Tag:

Regado Biosciences

Latest Headlines

Regado garners $40M Series D for clotting tech

December 18, 2009

Regado Biosciences has pulled together a $40 million Series D round to push the development of a new technology designed to give doctors better control over blood clots. Edmond de Rothschild

THE LIBRARY: WEBINAR

Getting the most PoC data in Phase I cancer studies

| June 12, 11am ET/ 8am PT

The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!

MORE ITEMS

EVENTS

MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
What's your BIO?June 18-21, 2012 — Boston, MA

MORE EVENTS

Press Releases

Featured Jobs

Director, Clinical Safety
Daiichi Sankyo - Edison, NJ
Director, Regulatory Affairs
Tesaro - Waltham, MA
Sr. Director, Healthcare Compliance Audit Job
Celgene Corporation - Summit, NJ, US
Entry Level Process Engineer and Lead Process Engineer
Foster Wheeler Biokinetics - San Francisco, CA
Clinical Research Associate / CRA Virology Job
Yoh - Danbury, CT, USA

Regado Biosciences

Latest Headlines

Latest Headlines

Regado garners $40M Series D for clotting tech

THE LIBRARY: WEBINAR

EVENTS

Press Releases

Featured Jobs

A publication of FierceMarkets

The FierceMarkets Network:

Telecom

Healthcare

Government

Energy

Life Sciences

Enterprise IT

Finance

Regado Biosciences

Latest Headlines

Latest Headlines

Regado garners $40M Series D for clotting tech

Related Tags